Pharmaceuticals News and Research

RSS

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.

6 Jan 2014

Viewpoints: Stop 'bailout' of Obamacare; health law not to blame for all insurance woes; 'theft' of Medicare advantage money

Shrinking revenues and rising costs could bring on the "death spiral" - an unbalanced patient pool forcing huge premium increases (to restore revenue) that would further unbalance the patient pool as the young and healthy drop out. End result? Insolvency

6 Jan 2014

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.

From Chromatrap® - Porvair Sciences Ltd 6 Jan 2014

Jones Engineering Group to focus on pharmaceutical industries in Saudi Arabia

Jones Engineering Group is continuing to develop its presence in Saudi Arabia with a strategic focus on the food and beverage, pharmaceutical and health care industries. The leading international engineering contracting group has recently signed a deal with a major multinational FMCG client worth an estimated €20 million. Work on the project will commence immediately.

6 Jan 2014

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.

3 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

3 Jan 2014

Viewpoints: Michael Moore finds health law affordability 'a cruel joke'; can more marketing help sell insurance?

Now that the individual mandate is officially here, let me begin with an admission: Obamacare is awful. That is the dirty little secret many liberals have avoided saying out loud for fear of aiding the president's enemies, at a time when the ideal of universal health care needed all the support it could get. ... For many people, the "affordable" part of the Affordable Care Act risks being a cruel joke. ... And yet -- I would be remiss if I didn't say this -- Obamacare is a godsend (Michael Moore, 12/31/13).

3 Jan 2014

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Executive leadership from Rainbow Coral Corp., a fast-rising biotechnology company, will scout for new innovations and potential partnerships this month at the sixth annual Biotech Showcase in San Francisco.

3 Jan 2014

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

A compound derived from a traditional Chinese herbal medicine has been found effective at alleviating pain, pointing the way to a new nonaddictive analgesic for acute inflammatory and nerve pain, according to UC Irvine pharmacology researchers.

3 Jan 2014

New research shows that as we age, the thermogenic activity of brown fat gets reduced

As most people resolve themselves to lose weight this New Year, here's why it seems to get easier and easier to pack on unwanted pounds: New research published in the January 2014 issue of The FASEB Journal, shows that as we age, the thermogenic activity of brown fat is reduced. Brown fat is a "good" fat located in the backs of our necks that helps burn "bad" white fat around our bellies. Additionally, the researchers also discovered a possible metabolic on/off switch that could reactivate brown fat.

2 Jan 2014

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-Acute Coronary Syndrome patients.

2 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND.

30 Dec 2013

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Veloxis Pharmaceuticals A/S, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

Roughly 40 percent of all medications act on cells' G protein-coupled receptors (GPCRs). One of these receptors, beta 2 adrenergic receptor site (B2AR), naturally transforms between two base configurations; knowing the precise location of each of approximately 4,000 atoms is crucial for ensuring a snug fit between it and the drug.

28 Dec 2013

Takeda terminates development activities for fasiglifam (TAK-875)

Takeda Pharmaceutical Company Limited (Takeda) announced today that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety.

27 Dec 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Older adults with low back pain are interested in receiving co-managed care, shows study

The Foundation for Chiropractic Progress (F4CP), a not-for-profit organization dedicated to raising awareness about the value of chiropractic care, promotes the findings of a new study, "Perspectives of older adults on co-management of low back pain by doctors of chiropractic and family medicine physicians: a focus group study" (BMC Complementary & Alternative Medicine, 9.16.2013).

27 Dec 2013

Pharmaceuticals News and Research

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

Viewpoints: Stop 'bailout' of Obamacare; health law not to blame for all insurance woes; 'theft' of Medicare advantage money

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Jones Engineering Group to focus on pharmaceutical industries in Saudi Arabia

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

Viewpoints: Michael Moore finds health law affordability 'a cruel joke'; can more marketing help sell insurance?

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

New research shows that as we age, the thermogenic activity of brown fat gets reduced

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

Takeda terminates development activities for fasiglifam (TAK-875)

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Older adults with low back pain are interested in receiving co-managed care, shows study

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence